Savient Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 73   

Articles published

SVNTQ 0.0019
price chart
Bridgewater-based Savient Pharmaceuticals OKd for Chapter 11 plan
Savient Pharmaceuticals Inc., a developer of a treatment for gout before its business was sold, got approval of a liquidating Chapter 11 plan, with U.S.
Savient Pharmaceuticals Files for Bankruptcy
(Corrects largest unsecured creditor in fourth paragraph of story published yesterday.) Savient Pharmaceuticals Inc. (SVNT), the developer of a treatment for gout, sought bankruptcy protection and court approval to sell its assets to a US WorldMeds LLC ...
Savient Pharmaceuticals Commences Voluntary Chapter 11 Proceeding; Seeks ...  PR Newswire (press release)
Savient Pharmaceuticals files for Chapter 11 bankruptcy  Yahoo News
Related articles »  
Savient Pharmaceuticals: Is Anything Left?
This is hardly enough to sustain the company, and it took a loss of $28.0 million for that quarter. With SVNT's current cash cushion of $96.3 million, it is clear that Savient will have to turn something around, and fast. Its prescription rates for ...
Savient Pharmaceuticals, Inc. (SVNT): Are Hedge Funds Right About This Stock?
When looking at the hedgies we track, William Leland Edwards's Palo Alto Investors had the most valuable position in Savient Pharmaceuticals, Inc. (NASDAQ:SVNT), worth close to $11.8 million, accounting for 1.4% of its total 13F portfolio. Coming in ...
Related articles »  
Savient Pharmaceuticals: Value Play Or Value Trap?
Savient Pharmaceuticals, Inc. (SVNT), based in East Brunswick, NJ is a biotechnology company engaged in the commercialization of Krystexxa (first and only in its class), for refractory chronic gout (RCG), an indication for which SVNT has obtained ...
Savient Pharmaceuticals: Glimmers Of Hope?
It's been a long arduous ride for Savient Pharmaceuticals Inc (SVNT). From a high of $28 all the way down to $0.62, investors have basically left this stock for dead.
Trying to Get a Handle on Savient Pharmaceuticals' Valuation
It is the same company that was selling for $22/share a few days ago. There have been no accounting irregularities. No new problems with the drug have been discovered.
Savient's Auction Didn't Result in Sale, Company Says  Bloomberg
Related articles »  
Savient Pharmaceuticals, Inc. v. Tang Capital Partners, LP, et al., C.A. No ...
Plaintiffs are note holders of Savient Pharmaceuticals, Inc. (�Savient� or the �Company�), whose principal asset is the worldwide ownership and license rights of the drug KRYSTEXXA.
Savient Pharmaceuticals: Sluggish Launch Of Krystexxa Presents Buying ...
Savient is an emerging biotechnology company that is in the early stages of launching its first product, Krystexxa (pegloticase) for chronic refractory gout patients.
Related articles »  
Savient Pharma Unveils Ch. 11 Plan
Law360, New York (February 10, 2014, 7:01 PM ET) -- Drug developer Savient Pharmaceuticals Inc. unveiled its Chapter 11 plans in Delaware bankruptcy court Monday, calling for the liquidation of its U.S.
Related articles »